Cambium Bio Limited (ASX:CMB)

Australia flag Australia · Delayed Price · Currency is AUD
0.450
0.00 (0.00%)
Apr 28, 2026, 3:10 PM AEST
55.17%
Market Cap 12.30M
Revenue n/a
Net Income n/a
Shares Out 27.33M
EPS n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 632
Average Volume 7,515
Open 0.410
Previous Close 0.450
Day's Range 0.410 - 0.450
52-Week Range 0.190 - 0.600
Beta -0.20
RSI 49.33
Earnings Date n/a

About Cambium Bio

Cambium Bio Limited, a clinical-stage regenerative medicine company, focuses on developing biologics for ophthalmology and tissue repair applications. The company provides lead product candidate is Elate Ocular for the treatment of dry eye disease. The company also develops Progenza, a stem cell platform for knee osteoarthritis and other tissue repair indications; and Sygenus, for wound healing indications. Cambium Bio Limited is headquartered in Bella Vista, Australia. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2013
Country Australia
Stock Exchange Australian Securities Exchange
Ticker Symbol CMB
Full Company Profile

News

There is no news available yet.